JP Industria Farmaceutica

What JP Industria Farmaceutica does

JP Industria Farmaceutica S/A (JP Farma) is a privately held Brazilian pharmaceutical manufacturer founded in 1966 and headquartered in Ribeirão Preto, São Paulo. The company operates three business units: (1) Infusion Therapies and Medicinal Solutions, including large-volume parenterals such as sodium chloride 0.9%, glucose 5% and 10%, Ringer's lactate, sodium bicarbonate 8.4%, mannitol, metronidazole, and other sterile solutions in PVC and polyethylene presentations; (2) Transfusion Technology and Biotechnology, encompassing standard and quadruple blood bags (CPD SAG Manitol, CPDA-1, transfer bags), ACD anticoagulant solution for apheresis, the Cordbag umbilical-cord-blood collection system, EVA-based Cryostore cryopreservation bags rated to -196°C, and blood-bank equipment (Bagmixer, Easy Sealer JP, JPmatic fractionator, OL4600 centrifuge) produced by subsidiary Olidef Medical; and (3) Veterinary Products and contract manufacturing services for third-party pharmaceutical firms, primarily in ophthalmology.

The company makes money primarily through direct B2B hardware sales of pharmaceuticals and medical equipment to hospitals, clinics, blood banks, and veterinary customers across Brazil, plus export sales to more than 50 countries in Latin America, Asia, Africa, and Europe via distributor networks. Pricing is not publicly disclosed and all sales are institutional; go-to-market is sales-led, with a direct sales force covering 14 Brazilian states plus the Federal District, supported by participation in Hospitalar, Arab Health, MEDICA, HEMO, and ABRASP trade events, and a Portuguese/English/Spanish website with WhatsApp Business contact. Manufacturing runs from two facilities — the original Ribeirão Preto plant (in operation since 1978) and a new Viamão (RS) unit inaugurated in June 2025/2026 — with wholly-owned subsidiary Olidef CZ Ind. e Com. de Aparelhos Hospitalares Ltda. (acquired 1986) supplying medical-hospital equipment. The workforce exceeds 900 direct employees and 1,000+ collaborators across the three units as of 2026.

Name

JP Industria Farmaceutica

Legal name

JP Indústria Farmacêutica S/A

Website

https://jpfarma.com.br

Company type

Private

Founded year

1966

Operating status

Operating

Headcount range

101–250 employees

Short description

JP Industria Farmaceutica is a Brazilian pharmaceutical manufacturer founded in 1966 that produces parenteral solutions, blood bags, cryopreservation products, and neonatal medical equipment for hospitals, clinics, blood banks, and veterinary customers in Brazil and 50+ export markets.

Ownership category

akta.pro rank

Product category

Sterile Pharmaceutical Manufacturing (Parenteral Solutions and Blood Bank Products)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Drug Product Fill-Finish & Aseptic Manufacturing Services (HLAAAKAB)

akta.pro secondary industries

Parenteral & Injectable Packaging Components (Stoppers, Seals, Syringes, Cartridges) (IMALAIAE), Sample Logistics, Biorepository & IVD Kit Management (Trial Support) (HLAGAEAI), Bioprocess Consumables & Reagents (resins, membranes, media components, buffers) (HLAAAJAI)

Keywords

• Parenteral solutions manufacturing
• Blood collection bags
• Infusion therapy products
• Neonatology medical equipment
• Contract pharmaceutical manufacturing

Headquarters

HQ city

São Paulo

HQ country

Brazil

HQ region

Latin America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Products Manufacturing: Manufacturing and sale of parenteral solutions (infusion therapies), sterile solutions, blood bags, and biotechnology products for domestic and export markets
2. Medical Equipment Sales: Sale of medical-hospital equipment manufactured by Olidef Medical including blood bank equipment, neonatology devices, and multiparametric monitors
3. Third-Party Manufacturing Services: Contract manufacturing services for other pharmaceutical companies, primarily in the ophthalmological sector
4. Veterinary Products: Sale of parenteral solutions and blood collection bags for veterinary use in small, medium, and large animals

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

JP Farma manufactures and sells large volume parenteral solutions (IV fluids such as saline, glucose, Ringer's lactate, sodium bicarbonate), sterile medicinal solutions (mannitol, metronidazole, glycine irrigation), blood collection and storage bags, anticoagulant solutions, and biotechnology products for umbilical cord blood and cryopreservation. Through its subsidiary Olidef Medical, it also produces medical-hospital equipment including blood bank devices (JPmatic, Bagmixer, Easy Sealer, OL4600 centrifuge), neonatology equipment (incubators, bilirubinometers, phototherapy), and multiparametric monitors. The company additionally provides contract manufacturing services to other pharmaceutical firms, primarily in ophthalmology.

Product overview

JP Farma (JP Indústria Farmacêutica) is a pharmaceutical company established in 1966 operating in three main business segments: (1) Infusion Therapies and Medicinal Solutions including parenteral solutions like water for injection, physiological solution, glucose solutions, Ringer's solutions, and specialized solutions (mannitol, metronidazol, enema, lactasol); (2) Transfusion Technology and Biotechnology encompassing blood collection bags (Standard, CPD-SAG-Manitol), anticoagulant solutions, cord blood collection (Cordbag), cryopreservation (Cryostore), and blood bank equipment (Bagmixer, Easy Sealer JP, JPmatic, OL4600) manufactured by sister company Olidef Medical; (3) Veterinary Products including animal blood collection bags and large-volume parenteral solutions. The company also offers contract manufacturing services for third-party pharmaceutical companies, primarily in ophthalmology. Products are distributed to more than 50 countries worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

• Água para injeção (Water for Injection) Injectable sterile water solution used for dilution or dissolution of compatible medications. Available in 250 mL, 500 mL, and 1 L presentations. Cannot be administered directly intravenously due to hypotonicity. Sold to healthcare institutions.
• Fisiológico (Physiological Solution 0.9%) Injectable sodium chloride 0.9% solution in closed system PVC bags for fluid and electrolyte restoration, rehydration, electrolyte replacement, and as a diluent for medications. Available in 100 mL, 250 mL, 500 mL, and 1 L presentations.
• Glicofisiológico 5% Injectable solution of glucose 5% + sodium chloride 0.9% indicated for dehydration treatment and as an energy medication.
• Glicose 5% (Dextrose 5%) Injectable dextrose 5% solution used as a source of water, calories, and osmotic diuresis for dehydration treatment, hypoglycemia, and as a vehicle for compatible drug dilution.
• Glicose 10% (Dextrose 10%) Injectable dextrose 10% solution used as source of water, calories, and osmotic diuresis, particularly in carbohydrate parenteral nutrition regimens.
• Ringer com Fisiológico (Ringer's Solution) Injectable solution of sodium chloride + potassium chloride + calcium chloride 2H2O for rehydration and restoration of fluid and electrolyte balance. Available in 500 mL presentation.
• Ringer com Lactato (Lactated Ringer's) Injectable solution of sodium chloride + potassium chloride + calcium chloride + sodium lactate for rehydration, fluid-electrolyte balance restoration, and prophylaxis/treatment of metabolic acidosis. Available in 250 mL, 500 mL, and 1 L presentations.
• Solução de Bicarbonato de Sódio 8,4% Injectable sodium bicarbonate 8.4% solution for treatment of metabolic acidosis, kidney disease, uncontrolled diabetes, circulatory failure, shock, dehydration, bleeding, cardiac arrest, lactic acidosis, non-specific detoxification, and urinary alkalization.
• Manitol 3% – 3L (Urological Irrigation) 3% mannitol solution used as an irrigating fluid in urological procedures.
• Manitol 20% Injectable mannitol 20% solution in closed system for promoting diuresis, prevention of acute renal failure during cardiovascular surgeries, reduction of intracranial and intraocular pressure, treatment of cerebral edema, and excretion of toxic substances. Available in PVC bags and polyethylene bottles of 250 mL.
• Água de Irrigação – 3L Irrigation water used as an irrigating fluid in urological procedures.
• Glicina 1,5% 1.5% glycine solution used as an irrigating fluid in urological procedures.
• Clisterol 12% 12% glycerin solution in sterile plastic bottles of 500 mL for intestinal washing (enema/clister).
• Enema Solution of monobasic sodium phosphate monohydrate and dibasic sodium phosphate heptahydrate for constipation relief and as a laxative. Available in sterile plastic bottles of 125 mL with rectal catheter.
• Lactasol 5-liter bag composed of sodium chloride, magnesium chloride, calcium chloride, and sodium lactate solution indicated for continuous arteriovenous hemofiltration (CAVH), continuous venovenous hemofiltration (CVVH), or continuous venovenous hemodiafiltration (CVVHDF).
• Metronidazol

Quantifiable outcome

• 60 years of continuous operation in pharmaceutical industry
• +3 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Six partnerships are on record, tiered strategic, core, flagship and minor.

• BirthTechstrategicStrategic or Co-development Partner · 27 March 2023New partnership announced in March 2023 between BirthTech and Olidef Medical for development and commercialization of products in the birth/maternal health technology space.
• FMRP-USP (Faculdade de Medicina de Ribeirão Preto)coreStrategic or Co-development Partner · 4 January 2016Partnership with University of São Paulo's Medical School in Ribeirão Preto for development of the Bilirrubinômetro AG device - a pioneering technology for minimally invasive bilirubin measurement in newborns. The device uses technology that is pioneering in the world market, developed with support from university faculty.
• Hospital de AmorflagshipStrategic or Co-development PartnerLong-standing support for Hospital de Amor, one of Brazil's largest oncology treatment centers with 60+ years of history and 100% free care. JP Group supports various initiatives including Elderly Support Project, Cuidar Project for children and adolescents in cancer treatment, and cultural incentive programs. Received 'Empresa Amiga' recognition in 2026.
• Casa das MangueirasminorStrategic or Co-development PartnerSocial support organization for youth at social risk. JP Farma provides monthly contributions supporting various community projects including youth labor market inclusion programs.
• Instituto Ribeirão 2030strategicStrategic or Co-development PartnerPartner in TecJovem project - innovative programming course for low-income public school youth, in partnership with Fundação Educandário. JP supports and sponsors this technology education initiative.
• Supera ParqueminorStrategic or Co-development PartnerJP Group participates in the Construction of the Innovation Radar project together with Superlab at Supera Parque, supporting regional innovation ecosystem development.

Scale indicators7 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• Fanem: Brazilian manufacturer of medical-hospital equipment including incubators, phototherapy units, and neonatal devices. Direct peer to Olidef Medical in the Brazilian neonatology equipment segment.
• Eurofarma: Brazilian pharmaceutical company with operations across multiple therapeutic areas including injectable products. Similar profile as a private Brazilian pharma manufacturer competing in similar domestic hospital and clinic channels.
• Terumo BCT: Global specialist in blood component collection, processing, and storage equipment, including blood bags and apheresis disposables. Directly comparable to JP Farma's transfusion technology segment including CPD SAG Manitol bags and ACD anticoagulant solutions.
• Macopharma: French manufacturer of blood collection bags, transfusion disposables, and bioprocessing solutions. Closely comparable to JP Farma's blood bag portfolio and cord blood/cryopreservation product line.
• Fresenius Kabi: Global leader in parenteral nutrition, IV fluids, and blood collection bags. Directly comparable to JP Farma's core infusion therapy and transfusion technology segments, competing head-to-head in Brazilian hospital tenders and international blood bag markets.
• Cristália: Brazilian pharmaceutical manufacturer specializing in hospital products including injectable solutions, anesthetics, and blood bank reagents. Closest Brazilian-headquartered peer in terms of product mix and customer base.
• B. Braun: Major manufacturer of IV solutions, infusion equipment, and surgical instruments with strong presence in Brazil. Comparable across JP Farma's parenteral solutions line and the medical equipment range through Olidef Medical.

Broad incumbents

• Baxter International: Multinational medical products company with significant parenteral solutions and IV bag portfolio, including Viaflo and other brands. A broader incumbent competing in similar hospital channels across multiple continents.
• EMS: One of Brazil's largest pharmaceutical manufacturers with a broad portfolio including hospital injectables. Comparable as a Brazilian domestic competitor in pharmaceutical manufacturing, though larger and broader than JP Farma.
• Grifols: Global plasma-derived medicines and blood-banking solutions provider with a meaningful position in blood collection bags and transfusion medicine. Comparable across the transfusion technology segment though broader in plasma products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/jpfarma
• LinkedInlinkedin.com/company/grupojpfarma

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about JP Industria Farmaceutica